



## 17. REFERENCIAS

- [1] Ordenación Sanitaria de la Junta de Castilla y León. <http://www.saludcastillayleon.es> - institución - organización - Ordenación del Sistema Sanitario.
- [2] HealthCast 2020: Creando un futuro sostenible, (2006). Health Research Institut de PricewaterhouseCoopers.
- [3] Gerencia Regional de Salud. Estrategia [e-salud] en Tecnologías de la Información y de la Comunicación de la Gerencia Regional de Salud, (2011). Consejería de Sanidad, Junta de Castilla y León .Valladolid.
- [4] III Plan de Salud de la Junta de Castilla y León. <http://www.saludcastillayleon.es> - institución - planes y estrategias.
- [5] Estrategia Regional de Investigación Científica, Desarrollo Tecnológico e Innovación de Castilla y León 2007-2013. Junta de Castilla y León. Valladolid 2007.
- [6] Plan de Calidad 2010-2014 del Sistema Sanitario Público de Castilla y León.
- [7] Juan Nieto Pajares. Historia clínica electrónica en el área de salud de Ávila. *Revistaesalud.com*. Vol 7, No 25 (2011).
- [8] Guía de Elementos Comunes de Mensajería. <http://www.saludcastillayleon.es> - Empresas - Estándares de Integración - Elementos comunes de mensajería HL7 2.5.
- [9] Guía ADT datos de personas. <http://www.hl7spain.org> - documentos - Guia ADT.
- [10] Políticas y Guías de Integración de Aplicaciones . <http://www.saludcastillayleon.es> - Empresas - Estándares de Integración - Presentación guías de mensajería.
- [11] Guía General de documentos clínicos en formato CDA. <http://www.saludcastillayleon.es> - Empresas - Estándares de Integración - Documentos Clínicos (CDA)
- [12] Guía de mensajería para gestión de imagen diagnóstica. <http://www.saludcastillayleon.es> - Empresas - Estándares de Integración - Guía de integración de imagen.
- [13] Video de ejemplo de realización de una sesión de teleoftalmología: integración de imágenes, inform, etc. <http://www.youtube.com/watch?v=ui4fuvekwY0>
- [14] José Luis Monteagudo Peña, Carlos Hernández Salvador y Fernando García-López. Metodología de introducción de servicios de e-salud para el seguimiento y control de pacientes crónicos. *Rev Esp Salud Pública* 2004; 78: 571-581.
- [15] Guía de Citas, Programaciones y Lista de espera. <http://www.saludcastillayleon.es> - Empresas - Estándares de Integración - Citas, programación quirúrgica y lista de espera.
- [16] Yogesan K. Kumar S. Goldschmidt L. Cuadros J. *Teleophthalmology*. New York: Springer-Verlag Berlin Heidelberg; 2006.
- [17] International Diabetes Federation. IDF Diabetes Atlas 5<sup>a</sup> edition (<http://www.idf.org/diabetesatlas/5e/es/prologo?language=es> ).
- [18] DCCT Research Group: The effect of intensive treatment of diabetes in the development and progression of long-term complications in insulin-dependent diabetes. *N Engl J Med* 329: 977-986, 1993.
- [19] UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 352: 837-853, 1998.
- [20] Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. *Arch Ophthalmol* 1984;102:520-6.
- [21] Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. *Arch Ophthalmol* 1984;102:527-32.
- [22] Retinopathy in diabetes (Position Statement). *Diabetes Care* 27 (Suppl. 1): S84-S87.
- [23] Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. *Arch Ophthalmol* 2004;122:552-63.
- [24] Ferris FL, III. How effective are treatments for diabetic retinopathy? *JAMA* 1993;269:1290-1.
- [25] American Diabetes Associations. Standards of medical care for patients with diabetes mellitus. *Diabetes care* 2000; 23:S32-S42.
- [26] BD Mutiamel. Barrier to compliance with screening guidelines for diabetic retinopathy. *Ophthalmic Epidemiology* 1998; 6(1): 61-72.
- [27] Schoenfeld ER, Greene JM, Wu SY, Leske MC. Patterns of adherence to diabetes vision care guidelines: baseline findings from the Diabetic Retinopathy Awareness Program. *Ophthalmology* 2001;108:563-71.
- [28] Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retino-

pathy. ETDRS report number 9. *Ophthalmology* 1991;98:766-85.

[29] Ferris F. Early photocoagulation in patients with either type I or type II diabetes. *Trans Am Ophthalmol Soc* 1996;94:505-37.

[30] UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ* 1998;317:703-13.

[31] Snow V, Weiss KB, Mottur-Pilson C. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. *Ann Intern Med* 2003;138:587-92.

[32] Wilkinson CP, Ferris FL III, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. *Ophthalmology* 2003;110:1677-1682.

[33] Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. *Arch Ophthalmol* 1985;103:1796-806.

[34] The Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology* 2010;117:1064-1077.

[35] Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. *Ophthalmology*. 2011;118:615-625.

[36] Diabetic Retinopathy Study Research Group. Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study report number 14. *Int Ophthalmol Clin* 1987;27:239-53.

[37] Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of Diabetic Retinopathy Study findings. *Ophthalmology* 1978;85:82-106.

[38] Javitt JC, Canner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in type I diabetics. *Ophthalmology* 1989;96:255-64.

[39] Dasbach EJ, Fryback DG, Newcomb PA, et al. Cost-effectiveness of strategies for detecting diabetic retinopathy. *Med Care* 1991;29:20-39.

[40] Javitt JC, Aiello LP, Bassi LJ, et al. Detecting and treating retinopathy in patients with type I diabetes mellitus. Savings associated with improved implementation of current guidelines. *American Academy of Ophthalmology. Ophthalmology* 1991;98:1565-73; discussion 1574.

[41] Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. *Ann Intern Med* 1996;124:164-9.

[42] Ferris FL, III. How effective are treatments for diabetic retinopathy? *JAMA* 1993;269:1290-1.

[43] Gutiérrez MA, Asua J. Estudio de la eficiencia de una cámara de retina no midriática para el diagnóstico de retinopatía diabética. *Rev Clin Esp* 1998; 198: 194-199.

[44] Williams GA, Scott IU, Haller JA, et al. Single-field fundus photography for diabetic retinopathy screening: a report by the American Academy of Ophthalmology. *Ophthalmology* 2004;111:1055-62.

[45] Lin DY, Blumenkranz MS, Brothers RJ, Grosvenor DM. The sensitivity and specificity of single-field nonmydriatic monochromatic digital fundus photography with remote image interpretation for diabetic retinopathy screening: a comparison with ophthalmoscopy and standardized mydriatic color photography. *Am J Ophthalmol* 2002;134:204-13.

[46] Leese GP, Ellis JD, Morris AD, Ellingford A. Does direct ophthalmoscopy improve retinal screening for diabetic eye disease by retinal photography? *Diabet Med* 2002;19:867-9.

[47] Tang RA, Morales M, Ricur G, Schiffman JS. Telemedicine for eye care. *J Telemed Telecare* 2005; 11: 391-396.

[48] Gómez-Ulla F, Fernández MI, González F, Rey P, Rodríguez M, Rodríguez-Cid MJ et al. Digital retinal images and teleophthalmology for detecting and grading diabetic retinopathy. *Diabetes Care* 2002; 25: 1384-1389.

[49] Sender MJ, Montserrat S, Badia X, Maseras M, De la Puente ML, Foz M. Non mydriatic retinal camera: cost-effectiveness study for early detection of diabetic retinopathy. *Med Clin(Barc)* 2003; 121: 446-452.

[50] Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. *Ophthalmology* 1992;99:933-43.

[51] Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study. I. Outline and major prevalence findings. *Am J Epidemiol* 1977;106:17-32.

[52] Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. *Arch Ophthalmol* 2004;122:477-85.

[53] Pascolini D, Mariotti S, Pokharel GP, Pararajasegaram R, Etya'ale D, Négrel A-D, et al. 2002 Global update of available data on visual impairment: a compilation of population-based prevalence studies. *Ophthalmic Epidemiology*, 2004;11:67-115.

[54] Pascolini D, Mariotti SPM. Global estimates of visual impairment: 2010. *Br J Ophthalmol* [Published Online First: 1 December 2011](https://doi.org/10.1136/bjophthalmol-2011-300539).

[55] Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on

- visual impairment in the year 2002. *Bulletin of the World Health Organization* 2004;82:844-851.
- [56] World Health Organization. VISION 2020: The Right to Sight. Global initiative for the elimination of the avoidable blindness. Action Plan 2006-2011. Publication of the World Health Organization. France. 2007.
- [57] World Health Organization . Action plan for the prevention of avoidable blindness and visual impairment, 2009-2013. WHO Document Production Services, Geneva, Switzerland. 2010.
- [58] West S, Sommer A. Prevention of blindness and priorities for the future. *Bulletin of the World Health Organization*, 2001, 79: 244–248.
- [59] Spanish Eyes Epidemiological (SEE) Study Group. Prevalence of age-related macular degeneration in Spain. *Br J Ophthalmol*. 2011 Jul;95(7):931-6.
- [60] Oliva G, Navarro L. Degeneración macular asociada a la edad: estrategias actuales en el tratamiento. Madrid: Plan de Calidad para el Sistema Nacional de Salud. Ministerio de Ciencia e Innovación. Agència d'Avaluació de Tecnologia i Recerca Mèdiques de Catalunya; 2009. Informes de Evaluación de Tecnologías Sanitarias, AATRM núm. 2007/09.
- [61] World Health Organization. The global burden of disease: 2004 update. Publication of the World Health Organization. Switzerland. 2008.
- [62] Frick KD, Foster A. The Magnitude and Cost of Global Blindness: An Increasing Problem That Can Be Alleviated. *Am J Ophthalmol* 2003;135:471–476.
- [63] Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. *Arch Ophthalmol* 2006;124:1754-60.
- [64] Coleman AL, Yu F. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999. *Ophthalmology* 2008;115:18-25.
- [65] Gottlieb JL. Age-related macular degeneration. *JAMA*. 2002;288(18):2233-6.
- [66] Bird AC, Bressler NB, Bressler SB et al. The international ARM Epidemiological Study Group: An international classification and grading system for age-related maculopathy and age-related macular degeneration. *Surv Ophthalmol* 1995;39:367-374.
- [67] De Jong PT. Age-related macular degeneration. *N Engl J Med*. 2006;355(14):1474-85.
- [68] Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. Complement factor H polymorphism in age-related macular degeneration. *Science*. 2005;308(5720):385-9.
- [69] Rivera A, Fischer S, Fritsche L, Keilhauer C, Lichtner P, Meitinger T, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. *Hum Mol Genet*. 2005;14(21):3227-36.
- [70] Lu M, Adamis AP. Molecular biology of choroidal neovascularization. *Ophthalmol Clin North Am*. 2006;19:323-324.
- [71] Pauleikhoff D, Chen JC, Chisholm IH, Bird AC. Choroidal perfusion abnormalities in age-related macular disease. *Am J Ophthalmol* 1990;109:211.
- [72] Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. *Ophthalmology*. 2001;108(4):697-704.
- [73] Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. *N Engl J Med*. 2000;342(7):483-92.
- [74] Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. *Ophthalmology*. 1997;104(1):7-21.
- [75] Arnold JJ, Sarks SH. Extracts from «clinical evidence»: age related macular degeneration. *BMJ*. 2000;321(7263):741-4.
- [76] Schaumberg DA, Christen WG, Hankinson SE, Glynn RJ. Body mass index and the incidence of visually significant age-related maculopathy in men. *Arch Ophthalmol*. 2001;119(9):1259-65.
- [77] Khan JC, Thurlby DA, Shahid H, et al. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. *Br J Ophthalmol* 2006;90:75-80.
- [78] Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. *Arch Ophthalmol* 2006;124:995-1001.
- [79] Fraser-Bell S, Wu J, Klein R, et al. Smoking, alcohol intake, estrogen use, and age-related macular degeneration in Latinos: the Los Angeles Latino Eye Study. *Am J Ophthalmol* 2006;141:79-87.
- [80] Tan JS, Mitchell P, Kifley A, et al. Smoking and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. *Arch Ophthalmol* 2007;125:1089-95.
- [81] Klein R, Knudtson MD, Cruickshanks KJ, Klein BE. Further observations on the association between smoking and the long-term incidence and progression of age-related macular degeneration: the Beaver Dam Eye

- Study. *Arch Ophthalmol* 2008;126:115-21.
- [82] Hyman L, Schachat AP, He Q, Leske MC. Age-Related Macular Degeneration Risk Factors Study Group. Hypertension, cardiovascular disease, and age-related macular degeneration. *Arch Ophthalmol* 2000;118:351-8.
- [83] Mares-Perlman JA, Fisher AI, Klein R, et al. Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. *Am J Epidemiol* 2001;153:424-32.
- [84] SanGiovanni JP, Chew EY, Clemons TE, et al. The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS report number 20. *Arch Ophthalmol* 2007;125:671-9.
- [85] Seddon JM, George S, Rosner B, Rifai N. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. *Arch Ophthalmol* 2005;123:774-82.
- [86] Schaumberg DA, Christen WG, Buring JE, et al. High-sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular degeneration in women. *Arch Ophthalmol* 2007;125:300-5.
- [87] Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? *Br J Ophthalmol*. 2003;87(3):312-7.
- [88] Augood CA, Vingerling JR, de Jong PT, Chakravarthy U, Seland J, Soubrane G, et al. Prevalence of age-related maculopathy in older europeans: the European Eye Study (EUREYE). *Arch Ophthalmol*. 2006;124(4):529-35.
- [89] Van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. *Arch Ophthalmol*. 2003;121(4):519-26.
- [90] Klein R, Klein BEK, Jensen SC, Meuer SN. The five-year incidence and progression of age-related maculopathy. *Ophthalmology* 1997;104:7-21.
- [91] Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. *Arch Ophthalmol*. 1997;115(6):741-7.
- [92] Ferris FL, Davis MD, Clemons TE, et al. A simplified severity scale for age-related macular degeneration: AREDS report number 18. *Arch Ophthalmol* 2005;123:1570-4.
- [93] Chopdar A, Chakravarthy U, Verma D. Age related macular degeneration. *BMJ*. 2003;326(7387):485-8.
- [94] The Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report number 8. *Arch Ophthalmol* 2001;119:1417-36.
- [95] Vedula S, Krzystolik M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. *Cochrane Database Syst Rev* 2008, Issue 2. Art. No.: CD005139. DOI: 10.1002/14651858.CD005139.pub2.
- [96] Ng EWM, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. *Nat Drug Disc*. 2006;5:123-23.
- [97] Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. *Retina*. 2006;26(8):859-70.
- [98] Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. *Ophthalmology* 2006;113:363-372.
- [99] Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. *Cochrane Database Syst Rev* 2008, Issue 2. Art. No.: CD000165. DOI: 10.1002/14651858.CD000165.pub3.
- [100] American Academy of Ophthalmology retina panel. Preferred practice pattern guidelines. Age-related macular degeneration. San Francisco, CA: American Academy of Ophthalmology; 2008. Disponible en: <http://www.aao.org/ppp>
- [101] Gerhs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration: emerging pathogenetic and therapeutic concepts. *Ann Med* 2006;38:450-71.
- [102] Soubrane G, Cruess A, Lotery A, et al. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. *Arch Ophthalmol* 2007;125:1249-54.
- [103] Wong T, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. *Ophthalmology* 2008;115:116-26.
- [104] Pirbhai A, Sheidow T, Hooper P. Prospective evaluation of digital non-stereo color fundus photography as a screening tool in age-related macular degeneration. *Am J Ophthalmol* 2005; 139: 455-461.
- [105] Le Tien V, Strehlo M, D'Athis P, Taillandier-Herliche E, Paillaud E, Mahiddine H et al. Interobserver and intraobserver reliability of detecting age-related macular degeneration using a nonmydriatic digital camera. *Am J Ophthalmol* 2008; 146: 520-526.
- [106] Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment

of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. - Hypertension. 2003 Dec;42(6):1206-52.

[107] Hemmelgarn BR, McAllister FA, Myers MG, McKay DW, Bolli P, Abbott C, Schiffrin EL, Grover S, Honos G, Lebel M, Mann K, Wilson T, Penner B, Tremblay G, Tobe SW, Feldman RD; Canadian Hypertension Education Program. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. *Can J Cardiol*. 2005 Jun;21(8):645-56.

[108] European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. *J Hypertens*. 2003 Jun;21(6):1011-53.

[109] Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Thom SM; BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV). *BMJ*. 2004 Mar 13;328(7440):634-40.

[110] 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. *J Hypertens*. 1999 Feb;17(2):151-83.

[111] Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003 Nov;21(11):1983-92

[112] van den Born BJ, Hulsman CA, Hoekstra JB, Schlingemann RO, van Montfrans GA. Value of routine funduscopy in patients with hypertension: systematic review. *BMJ*. 2005 Jul 9;331(7508):73.

[113] Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003 May 21;289(19):2560-72.

[114] Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM, Kiowski W, Kjeldsen S, Lüscher T, Mallion JM, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, van Zwieten P, Waeber B, Williams B, Zanchetti A; ESH/ESC Hypertension Guidelines Committee. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. - *J Hypertens*. 2003 Oct;21(10):1779-86.

[115] Hayreh SS. Systemic arterial blood pressure in the eye. Duke-Elder Lecture. *Eye* 1996;10:5-28.

[116] Rath EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein occlusions. A case-control study. *Ophthalmology* 1992; 99: 509-14.

[117] Tso MOM, Jampol LM. Pathophysiology of hypertensive retinopathy. *Ophthalmology* 1982;89:1132-45.

[118] Sanchez Salorio M. Hipertensión Arterial. Manifestaciones Oftalmológicas de las enfermedades sistémicas. Ponencia oficial de la Sociedad Española de Oftalmología 2001.

[119] Wong TY, Hubbard LD, Klein R, Marino EK, Kronmal R, Sharrett AR, Siscovick DS, Burke G, Tielsch JM. Retinal microvascular abnormalities and blood pressure in older people: the Cardiovascular Health Study. *Br J Ophthalmol*. 2002 Sep;86(9):1007-13.

[120] Wang JJ, Mitchell P, Leung H, Rochtchina E, Wong TY, Klein R. Hypertensive retinal vessel wall signs in a general older population: the Blue Mountains Eye Study. *Hypertension*. 2003 Oct;42(4):534-41.

[121] Klein R, Klein BE, Moss SE. The relation of systemic hypertension to changes in the retinal vasculature: the Beaver Dam Eye Study. *Trans Am Ophthalmol Soc*. 1997;95:329-48; discussion 348-50.

[122] Klein R, Klein BE, Moss SE, Wang Q. Hypertension and retinopathy, arteriolar narrowing, and arteriovenous nicking in a population. *Arch Ophthalmol*. 1994 Jan;112(1):92-8.

[123] Wong TY, Duncan BB, Golden SH, Klein R, Couper DJ, Klein BE, Hubbard LD, Sharrett AR, Schmidt MI. Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk In Communities study. *Invest Ophthalmol Vis Sci*. 2004 Sep;45(9):2949-54.

[124] Wong TY, Shankar A, Klein R, Klein BE, Hubbard LD. Prospective cohort study of retinal vessel diameters and risk of hypertension. *BMJ*. 2004 Jul 10;329(7457):79. Epub 2004 Jun 2. Erratum in: *BMJ*. 2004 Aug 14;329(7462):384.

[125] Smith W, Wang JJ, Wong TY, Rochtchina E, Klein R, Leeder SR, Mitchell P. Retinal arteriolar narrowing is associated with 5-year incident severe hypertension: the Blue Mountains Eye Study. *Hypertension*. 2004 Oct;44(4):442-7.

[126] Svärdsudd K, Wedel H, Aurell E, Tibblin G. Hypertensive eye ground changes. Prevalence, relation to blood pressure and prognostic importance. The study of men born in 1913. *Acta Med Scand*. 1978;204(3):159-67.

[127] Ikram MK, de Jong FJ, Vingerling JR, Witteman JC, Hofman A, Breteler MM, de Jong PT. Are retinal arteriolar or venular diameters associated with markers for cardiovascular disorders? The Rotterdam Study. *Invest Ophthalmol Vis Sci*. 2004 Jul;45(7):2129-34.

[128] Wong TY, Klein R, Sharrett AR, Schmidt MI, Pankow JS, Couper DJ, Klein BE, Hubbard LD, Duncan BB; ARIC

Investigators. Retinal arteriolar narrowing and risk of diabetes mellitus in middle-aged persons. *JAMA*. 2002 May 15;287(19):2528-33.

[129] Wong TY, Shankar A, Klein R, Klein BE, Hubbard LD. Retinal arteriolar narrowing, hypertension, and subsequent risk of diabetes mellitus. *Arch Intern Med*. 2005 May 9;165(9):1060-5.

[130] Sharrett AR, Hubbard LD, Cooper LS, Sorlie PD, Brothers RJ, Nieto FJ, Pinsky JL, Klein R. Retinal arteriolar diameters and elevated blood pressure: the Atherosclerosis Risk in Communities Study. *Am J Epidemiol*. 1999 Aug 1;150(3):263-70.

[131] Leung H, Wang JJ, Rochtchina E, Wong TY, Klein R, Mitchell P. Impact of current and past blood pressure on retinal arteriolar diameter in an older population. *J Hypertens*. 2004 Aug;22(8):1543-9.

[132] Leishman R. The eye in general vascular disease: hypertension and arteriosclerosis. *Br J Ophthalmol*. 1957 Nov;41(11):641-701.

[133] Grosso A, Veglio F, Porta M, Grignolo FM, Wong TY. Hypertensive retinopathy revisited: some answers, more questions. *Br J Ophthalmol*. 2005 Dec;89(12):1646-54.

[134] Wong TY, Klein R, Sharrett AR, Duncan BB, Couper DJ, Klein BE, Hubbard LD, Nieto FJ; Atherosclerosis Risk in Communities Study. Retinal arteriolar diameter and risk for hypertension. *Ann Intern Med*. 2004 Feb 17;140(4):248-55.

[135] Sharp PS, Chaturvedi N, Wormald R, McKeigue PM, Marmot MG, Young SM. Hypertensive retinopathy in Afro-Caribbeans and Europeans. Prevalence and risk factor relationships. *Hypertension*. 1995 Jun;25(6):1322-5.

[136] Wong TY, Klein R, Duncan BB, Nieto FJ, Klein BE, Couper DJ, Hubbard LD, Sharrett AR. Racial differences in the prevalence of hypertensive retinopathy. *Hypertension*. 2003 May;41(5):1086-91.

[137] Wong TY, Klein R, Sharrett AR, Manolio TA, Hubbard LD, Marino EK, Kuller L, Burke G, Tracy RP, Polak JF, Gottdiener JS, Siscovick DS. The prevalence and risk factors of retinal microvascular abnormalities in older persons: The Cardiovascular Health Study. *Ophthalmology*. 2003 Apr;110(4):658-66.

[138] Pontremoli R, Sofia A, Ravera M, Nicoletta C, Viazzi F, Tirota A, Ruello N, Tomolillo C, Castello C, Grillo G, Sacchi G, Deferrari G. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. *Microalbuminuria: A Genoa Investigation on Complications*. *Hypertension*. 1999;30(5):1135-43.

[139] Cerasola G, Cottone S, Mulé G, Nardi E, Mangano MT, Andronico G, Contorno A, Li Vecchi M, Galione P, Renda F, Piazza G, Volpe V, Lisi A, Ferrara L, Panepinto N, Riccobene R. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. *J Hypertens*. 1996;14(7):915-20.

[140] Wong TY, Coresh J, Klein R, Muntner P, Couper DJ, Sharrett AR, Klein BE, Heiss G, Hubbard LD, Duncan BB. Retinal microvascular abnormalities and renal dysfunction: the atherosclerosis risk in communities study. *J Am Soc Nephrol*. 2004;15(9):2469-76.

[141] Edwards MS, Wilson DB, Craven TE, Stafford J, Fried LF, Wong TY, Klein R, Burke GL, Hansen KJ. Associations between retinal microvascular abnormalities and declining renal function in the elderly population: the Cardiovascular Health Study. *Am J Kidney Dis*. 2005;46(2):214-24.

[142] Wong TY, Klein R, Nieto FJ, Klein BE, Sharrett AR, Meuer SM, Hubbard LD, Tielsch JM. Retinal microvascular abnormalities and 10-year cardiovascular mortality: a population-based case-control study. *Ophthalmology*. 2003 May;110(5):933-40.

[143] Wong TY, Klein R, Couper DJ, Cooper LS, Shahar E, Hubbard LD, Wofford MR, Sharrett AR. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. *Lancet*. 2003;358(9288):1134-40.

[144] National Collaborating Centre for Acute Care. Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension. Methods, evidence & guidance. Available at: [www.nice.org.uk/nice-media/live/12145/43887/43887.pdf](http://www.nice.org.uk/nice-media/live/12145/43887/43887.pdf). 2009.

[145] Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol* 2006;90:262-7.

[146] Zafra Pérez JJ, Villegas Pérez MP, Canteras Jordana M, Miralles De Imperial J. Presión intraocular y prevalencia de glaucoma oculto en una población de la región de Murcia. *Arch Soc Esp Oftalmol*. 2000 Mar;75(3):171-8.

[147] Antón A, Andrada MT, Mujica V, Calle MA, Portela J, Mayo A. Prevalence of primary open-angle glaucoma in a Spanish population: the Segovia study. *J Glaucoma*. 2004 Oct;13(5):371-6.

[148] Quigley HA, Jampel HD. How are glaucoma patients identified?. *J Glaucoma* 2003 Dec;12(6):451-5.

[149] Janz NK, Wren PA, Lichter PR, Musch DC, Gillespie BW, Guire KE, Mills RP; CIGTS Study Group. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. *Ophthalmology* 2001;108(11):1954-65.

[150] Janz NK, Wren PA, Lichter PR, Musch DC, Gillespie BW, Guire KE. Quality of life in newly diagnosed glaucoma patients : The Collaborative Initial Glaucoma Treatment Study. *Ophthalmology* 2001;108(5):887-97; discussion 898.

- [151] Freeman EE, Muñoz B, Rubin G, West SK. Visual field loss increases the risk of falls in older adults: the Salisbury eye evaluation. *Invest Ophthalmol Vis Sci* 2007;48(10):4445-50.
- [152] Coleman AL, Cummings SR, Yu F, Kodjebacheva G, Ensrud KE, Gutierrez P, Stone KL, Cauley JA, Pedula KL, Hochberg MC, Mangione CM; Study Group of Osteoporotic Fractures. Binocular visual-field loss increases the risk of future falls in older white women. *J Am Geriatr Soc.* 2007 Mar;55(3):357-64.
- [153] Haymes SA, Leblanc RP, Nicolela MT, Chiasson LA, Chauhan BC. Risk of falls and motor vehicle collisions in glaucoma. *Invest Ophthalmol Vis Sci* 2007;48(3):1149-55.
- [154] McGwin G Jr, Xie A, Mays A, Joiner W, DeCarlo DK, Hall TA, Owsley C. Visual field defects and the risk of motor vehicle collisions among patients with glaucoma. *Invest Ophthalmol Vis Sci* 2005;46(12):4437-41.
- [155] American Academy of Ophthalmology. Primary open-angle glaucoma, preferred practice pattern. San Francisco: American Academy of Ophthalmology, 2010. Disponible en: [www.aao.org/ppp](http://www.aao.org/ppp).
- [156] Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. *Arch Ophthalmol* 1991;109:1090-5.
- [157] Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. *Ophthalmology* 1996;103:1661-9.
- [158] Leske MC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study. Prevalence of open angle glaucoma. *Arch Ophthalmol* 1994;112:821-9.
- [159] Quigley HA, West SK, Rodriguez J, et al. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. *Arch Ophthalmol* 2001;119:1819-26.
- [160] Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. *Surv Ophthalmol* 1980;24:335-610.
- [161] Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. *Ophthalmology* 1992;99:1499-504.
- [162] Weih LM, Nanjan M, McCarty CA, Taylor HR. Prevalence and predictors of open-angle glaucoma: results from the visual impairment project. *Ophthalmology* 2001;108:1966-72
- [163] Dielemans I, Vingerling JR, Wolfs RC, et al. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. *Ophthalmology* 1994;101:1851-5.
- [164] Wensor MD, McCarty CA, Stanislavsky YL, et al. The prevalence of glaucoma in the Melbourne Visual Impairment Project. *Ophthalmology* 1998;105:733-9.
- [165] Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. *JAMA* 1991;266:369-74.
- [166] Wolfs RC, Klaver CC, Ramrattan RS, et al. Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. *Arch Ophthalmol* 1998;116:1640-5.
- [167] Doshi V, Ying-Lai M, Azen SP, Varma R, Los Angeles Latino Eye Study Group. Sociodemographic, family history, and lifestyle risk factors for open-angle glaucoma and ocular hypertension. The Los Angeles Latino Eye Study. *Ophthalmology* 2008;115:639-47.
- [168] Tielsch JM, Katz J, Sommer A, et al. Family history and risk of primary open angle glaucoma. The Baltimore Eye Survey. *Arch Ophthalmol* 1994;112:69-73.
- [169] Varma R, Ying-Lai M, Francis BA, et al, Los Angeles Latino Eye Study Group. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. *Ophthalmology* 2004;111:1439-48.
- [170] Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. *JAMA* 1991;266:369-74.
- [171] Dueker DK, Singh K, Lin SC, et al. Corneal thickness measurement in the management of primary open-angle glaucoma: a report by the American Academy of Ophthalmology. *Ophthalmology* 2007;114:1779-87.
- [172] Francis BA, Varma R, Chopra V, et al, Los Angeles Latino Eye Study Group. Intraocular pressure, central corneal thickness, and prevalence of open-angle glaucoma: the Los Angeles Latino Eye Study. *Am J Ophthalmol* 2008;146:741-6.
- [173] Liu J, Roberts CJ. Influence of corneal biomechanical properties on intraocular pressure measurement: quantitative analysis. *J Cataract Refract Surg* 2005;31:146-55.
- [174] Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the Early Manifest Glaucoma Trial. *Ophthalmology* 2007;114:1965-72.
- [175] Bonomi L, Marchini G, Marraffa M, et al. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. *Ophthalmology* 2000;107:1287-93.
- [176] Memarzadeh F, Ying-Lai M, Chung J, et al, Los Angeles Latino Eye Study Group. Blood pressure, perfusion pressure, and open-angle glaucoma: the Los Angeles Latino Eye Study. *Invest Ophthalmol Vis Sci* 2010;51:2872-7.
- [177] Tielsch JM, Katz J, Sommer A, et al. Hypertension, perfusion pressure, and primary open-angle glaucoma.



- A population-based assessment. *Arch Ophthalmol* 1995;113:216-21.
- [178] Chopra V, Varma R, Francis BA, et al. Los Angeles Latino Eye Study Group. Type 2 diabetes mellitus and the risk of open-angle glaucoma: the Los Angeles Latino Eye Study. *Ophthalmology* 2008;115:227-32.
- [179] Pasquale LR, Kang JH, Manson JE, et al. Prospective study of type 2 diabetes mellitus and risk of primary open-angle glaucoma in women. *Ophthalmology* 2006;113:1081-6.
- [180] de Voogd S, Ikram MK, Wolfs RC, et al. Is diabetes mellitus a risk factor for open-angle glaucoma? The Rotterdam Study. *Ophthalmology* 2006;113:1827-31.
- [181] Klein BE, Klein R, Jensen SC. Open-angle glaucoma and older-onset diabetes. The Beaver Dam Eye Study. *Ophthalmology* 1994;101:1173-7.
- [182] Bonovas S, Peponis V, Filioussi K. Diabetes mellitus as a risk factor for primary open-angle glaucoma: a meta-analysis. *Diabet Med* 2004;21:609-14.
- [183] Wong TY, Klein BE, Klein R, et al. Refractive errors, intraocular pressure, and glaucoma in a white population. *Ophthalmology* 2003;110:211-7.
- [184] Wu SY, Nemesure B, Leske MC. Glaucoma and myopia. *Ophthalmology* 2000;107:1026-7.
- [185] Kuzin AA, Varma R, Reddy HS, et al. Ocular biometry and open-angle glaucoma: The Los Angeles Latino Eye Study. *Ophthalmology* 2010;117:1713-19.
- [186] Mitchell P, Hourihan F, Sandbach J, Wang JJ. The relationship between glaucoma and myopia: the Blue Mountains Eye Study. *Ophthalmology* 1999;106:2010-5.
- [187] Grodum K, Heijl A, Bengtsson B. Refractive error and glaucoma. *Acta Ophthalmol Scand* 2001;79:560-6.
- [188] Xu L, Wang Y, Wang S, Jonas JB. High myopia and glaucoma susceptibility the Beijing Eye Study. *Ophthalmology* 2007;114:216-20.
- [189] Wiggs JL. Genetic etiologies of glaucoma. *Arch Ophthalmol* 2007;125:30-7.
- [190] Wang J, Mitchell P, Smith W. Is there an association between migraine headache and open-angle glaucoma? Findings from the Blue Mountains Eye Study. *Ophthalmology* 1997;104:1714-19.
- [191] Broadway DC, Drance SM. Glaucoma and vasospasm. *Br J Ophthalmol* 1998;82:862-70.
- [192] Dielemans I, Vingerling JR, Algra D, et al. Primary open-angle glaucoma, intraocular pressure, and systemic blood pressure in the general elderly population. The Rotterdam Study. *Ophthalmology* 1995;102:54-60.
- [193] Mitchell P, Lee AJ, Rochtchina E, Wang JJ. Open-angle glaucoma and systemic hypertension: the Blue Mountains Eye Study. *J Glaucoma* 2004;13:319-26.
- [194] Leske MC, Wu SY, Nemesure B, Hennis A. Incident open-angle glaucoma and blood pressure. *Arch Ophthalmol* 2002;120:954-9.
- [195] Whitacre MM, Stein R. Sources of error with use of Goldmann-type tonometers. *Surv Ophthalmol* 1993;38:1-30.
- [196] Bagga H, Liu JH, Weinreb RN. Intraocular pressure measurements throughout the 24 h. *Curr Opin Ophthalmol* 2009;20:79-83.
- [197] Shah S, Chatterjee A, Mathai M, et al. Relationship between corneal thickness and measured intraocular pressure in a general ophthalmology clinic. *Ophthalmology* 1999;106:2154-60.
- [198] Sommer A, Katz J, Quigley HA, et al. Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss. *Arch Ophthalmol* 1991;109:77-83.
- [199] Baraibar B, Sanchez-Cano A, Pablo LE, Honrubia FM. Preperimetric glaucoma assessment with scanning laser polarimetry (GDx VCC): analysis of retinal nerve fiber layer by sectors. *J Glaucoma* 2007;16:659-64.
- [200] Lalezary M, Medeiros FA, Weinreb RN, et al. Baseline optical coherence tomography predicts the development of glaucomatous change in glaucoma suspects. *Am J Ophthalmol* 2006;142:576-82.
- [201] Izzeri G, Weinreb RN, Martinez de la Casa JM, et al. Clinicians agreement in establishing glaucomatous progression using the Heidelberg retina tomograph. *Ophthalmology* 2009;116:14-24.
- [202] Jonas JB, Bergua A, Schmitz-Walckenberg P, Papastathopoulos KL, Budde WM. Ranking of optic disc variables for detection of glaucomatous optic nerve damage. *Invest Ophthalmol Vis Sci* 2000;41:1764-1773.
- [203] Leske MC, Heijl A, Hussein M, et al, Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. *Arch Ophthalmol* 2003;121:48-56.
- [204] Delgado MF, Nguyen NT, Cox TA, et al. Automated perimetry: a report by the American Academy of Ophthalmology. *Ophthalmology* 2002;109:2362-74.
- [205] Chauhan BC, Mikelberg FS, Balaszi AG, et al. Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. *Arch Ophthalmol* 2008;126:1030-6.
- [206] Kwon YH, Kim YI, Pereira ML, et al. Rate of optic disc cup progression in treated primary open-angle glaucoma. *J Glaucoma* 2003;12:409-16.
- [207] Nouri-Mahdavi K, Medeiros FA, Weinreb RN. Fluctuation of intraocular pressure as a predictor of visual field progression. *Arch Ophthalmol* 2008;126:1168-9; author reply 9-70.

- [208] Jonas JB, Martus P, Horn FK, et al. Predictive factors of the optic nerve head for development or progression of glaucomatous visual field loss. *Invest Ophthalmol Vis Sci* 2004;45:2613-8.
- [209] Tezel G, Siegmund KD, Trinkaus K, et al. Clinical factors associated with progression of glaucomatous optic disc damage in treated patients. *Arch Ophthalmol* 2001;119:813-8.
- [210] Martus P, Stroux A, Budde WM, et al. Predictive factors for progressive optic nerve damage in various types of chronic open-angle glaucoma. *Am J Ophthalmol* 2005;139:999-1009.
- [211] Stewart WC, Kolker AE, Sharpe ED, et al. Factors associated with long-term progression or stability in primary open-angle glaucoma. *Am J Ophthalmol* 2000;130:274-9.
- [212] Jonas JB, Stroux A, Velten I, et al. Central corneal thickness correlated with glaucoma damage and rate of progression. *Invest Ophthalmol Vis Sci* 2005;46:1269-74.
- [213] Chauhan BC, Hutchison DM, LeBlanc RP, et al. Central corneal thickness and progression of the visual field and optic disc in glaucoma. *Br J Ophthalmol* 2005;89:1008-12.
- [214] Martus P, Stroux A, Budde WM, Mardin CY, Korth M, Jonas JB. Predictive factors for progressive optic nerve damage in various types of chronic open-angle glaucoma. *Am J Ophthalmol* 2005;139:999-1009.
- [215] Jampel HD. Target pressure in glaucoma therapy. *J Glaucoma* 1997;6(2):133-8.
- [216] Heijl A, Leske MC, Bengtsson B, et al, Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. *Arch Ophthalmol* 2002;120:1268-79.
- [217] AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. *Am J Ophthalmol* 2000;130:429-40.
- [218] Stamper RL, Wigginton SA, Higginbotham EJ. Primary drug treatment for glaucoma: beta-blockers versus other medications. *Surv Ophthalmol*. 2002;47(1):63-73.
- [219] Whitson JT. Glaucoma: a review of adjunctive therapy and new management strategies. *Expert Opin Pharmacother* 2007;8:3237-49.
- [220] McKinnon SJ, Goldberg LD, Peeples P, et al. Current management of glaucoma and the need for complete therapy. *Am J Manag Care* 2008;14:S20-7.
- [221] Stewart WC, Konstas AG, Nelson LA, Kruff B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. *Ophthalmology* 2008;115:1117-22.
- [222] Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). *Invest Ophthalmol Vis Sci* 2007;48:5052-7.
- [223] Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. *Am J Ophthalmol* 2004;137:S13-6.
- [224] Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. *Ophthalmology*. 2005 Jun;112(6):953-61.
- [225] Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. *Ophthalmology* 2009;116:191-9.
- [226] Hernandez RA, Burr JM, Vale LD. Economic evaluation of screening for open-angle glaucoma. *Int J Technol Assess Health Care* 2008;24:203-11..
- [227] Vaahtoranta-Lehtonen H, Tuulonen A, Aronen P, Sintonen H, Suoranta L, Kovanen N, Linna M, Läärä E, Malmivaara A. Cost effectiveness and cost utility of an organized screening programme for glaucoma. *Acta Ophthalmol Scand* 2007;85(5):508-18.
- [228] Burr JM, Mowatt G, Hernández R, Siddiqui MA, Cook J, Lourenco T, Ramsay C, Vale L, Fraser C, Azuara-Blanco A, Deeks J, Cairns J, Wormald R, McPherson S, Rabindranath K, Grant A. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. *Health Technol Assess* 2007;11(41):1-190.
- [229] Glaucoma screening Platform Study group, Burr JM, Campbell MK, Campbell SE, Francis JJ, Greene A, Hernández R, Hopkins D, McCann SK, Vale LD. Developing the clinical components of a complex intervention for a glaucoma screening trial: a mixed methods study. *BMC Med Res Methodol*. 2011 Apr 21;11:54.
- [230] U.S. Preventive Services Task Force. Screening for Glaucoma: Recommendation Statement. AHRQ Publication No. 04-0548-A, March 2005. (<http://www.uspreventiveservicestaskforce.org/uspstf05/glaucoma/glaucrs.htm>).
- [231] Tielsch JM, Katz J, Singh K, et al. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. *Am J Epidemiol* 1991;134:1102-10.
- [232] Lichter PR. Variability of expert observers in evaluating the optic disc. *Trans Am Ophthalmol Soc* 1976;74:532-72.

- [233] Tatemichi M, Nakano T, Tanaka K, et al. Performance of glaucoma mass screening with only a visual field test using frequency-doubling technology perimetry. *Am J Ophthalmol* 2002;134:529-37.
- [234] Li HK, Tang RA, Oschner K, Koplos C, Grady J, Crump WJ. Telemedicine screening of glaucoma. *Telemed J* 1999;5(3):283-90.
- [235] Khouri AS, Szirth BC, Salti HI, Fechtner RD. DICOM transmission of simultaneous stereoscopic images of the optic nerve in patients with glaucoma. *J Telemed Telecare* 2007;13(7):337-40.
- [236] Kumar S, Giubilato A, Morgan W, Jitskaia L, Barry C, Bulsara M, Constable IJ, Yogesan K. Glaucoma screening: analysis of conventional and telemedicine-friendly devices. *Clin Experiment Ophthalmol*. 2007 Apr;35(3):237-43.
- [237] Blázquez F, Sebastián MA, Antón A. Detection of glaucoma using SisGlaTel: acceptability and satisfaction among participants, and problems detected. *Arch Soc Esp Oftalmol* 2008;83(9):533-8.
- [238] Michelson G, Striebel W, Prihoda W, Schmidt V. Telemedicine in the control of intra-ocular pressure. *J Telemed Telecare*. 2000;6 Suppl 1:S126-8.
- [239] Tuulonen A, Ohinmaa T, Alanko HI, Hyytinen P, Juutinen A, Toppinen E. The application of teleophthalmology in examining patients with glaucoma: a pilot study. *J Glaucoma*. 1999;8:367-73.